80
Participants
Start Date
February 28, 2014
Primary Completion Date
October 31, 2015
Study Completion Date
November 30, 2015
Lucinactant for Inhalation
Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
nCPAP alone
nCPAP therapy
Christiana Care Health System, Newark
Duke University Medical Center, Durham
University of Miami, Miami
University of Alabama at Birmingham, Birmingham
University of Louisville, Louisville
Riley Hospital for Children at IU Health, Indianapolis
Arkansas Children's Hospital, Little Rock
Sharp Mary Birch Hospital for Women and Newborns, San Diego
Loma Linda University Medical Center, Loma Linda
Providence St. Vincent Medical Center, Portland
Mid Atlantic Neonatology Associates, Morristown
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Windtree Therapeutics
INDUSTRY